Sign in Subscribe
Pharmaceutical industry

BioSante Pharmaceuticals to Present at Three Healthcare Conferences

Strategic Insights

— 1 min read

BioSante Pharmaceuticals, Inc., a specialty pharmaceutical company focused on developing products for female sexual health and oncology, will present at three healthcare conferences in September 2011. The company will provide a company overview, update on LibiGel(R) Phase III clinical development program, and planned new drug application (NDA) submission at each conference. The presentations will be webcast live, and archives will be available for a limited time.

Key Takeaways:

  • BioSante Pharmaceuticals will present at three healthcare conferences in September 2011, including the Stifel Nicolaus Healthcare Conference, Rodman & Renshaw Healthcare Conference, and JMP Securities Healthcare Conference.
  • The company will provide a company overview, update on LibiGel(R) Phase III clinical development program, and planned NDA submission at each conference.
  • A live audio webcast of remarks by Phillip Donenberg and Stephen M. Simes will be available, and archives will be available for a limited time.
  • BioSante's lead product is LibiGel(R) (transdermal testosterone gel) for the treatment of female sexual dysfunction (FSD).
  • BioSante's first FDA-approved product is Elestrin™ (estradiol gel) indicated for the treatment of hot flashes associated with menopause, marketed in the U.S. by Azur Pharma.
  • BioSante is developing a portfolio of cancer vaccines, four of which have been granted Orphan Drug designation, and are currently in several Phase II clinical trials.

Statistics:

  • LibiGel(R) is in Phase III clinical development under a U.S. Food and Drug Administration (FDA) Special Protocol Assessment (SPA).
  • BioSante's first FDA-approved product, Elestrin™, was marketed in the U.S. by Azur Pharma.
  • Four of BioSante's cancer vaccines have been granted Orphan Drug designation.
  • BioSante's oral contraceptive is in Phase II clinical development using BioSante patented technology.

Sources:

  • BioSante Pharmaceuticals, Inc. press release, September 7, 2011
  • Stifel Nicolaus Healthcare Conference, 2011
  • Rodman & Renshaw Healthcare Conference, 2011
  • JMP Securities Healthcare Conference, 2011
  • U.S. Food and Drug Administration (FDA), LibiGel(R) Phase III clinical development program
  • Medical Letter on the CDC & FDA, 2011

Read more